BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

39 related articles for article (PubMed ID: 12649770)

  • 1. Second-generation antipsychotics and VTE risk.
    DeLoughery EP
    Eur J Haematol; 2024 Apr; ():. PubMed ID: 38644355
    [No Abstract]   [Full Text] [Related]  

  • 2. The estimation of utility weights in cost-utility analysis for mental disorders: a systematic review.
    Sonntag M; König HH; Konnopka A
    Pharmacoeconomics; 2013 Dec; 31(12):1131-54. PubMed ID: 24293216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging empirical evidence on the ethics of schizophrenia research.
    Dunn LB; Candilis PJ; Roberts LW
    Schizophr Bull; 2006 Jan; 32(1):47-68. PubMed ID: 16237201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
    Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
    J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [New antipsychotics in the treatment of schizophrenia. A European survey].
    Sarfati Y; Olivier V; Bouhassira M
    Encephale; 1999; 25(6):658-66. PubMed ID: 10668612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are the second-generation antipsychotics cost-effective? A critical review on the background of different health systems.
    Hamann J; Leucht S; Kissling W
    Pharmacopsychiatry; 2003 Jan; 36(1):18-26. PubMed ID: 12649770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methods of cost-effectiveness analysis in the evaluation of new antipsychotics: implications for schizophrenia treatment.
    Neumann PJ
    J Clin Psychiatry; 1999; 60 Suppl 3():9-14; discussion 15. PubMed ID: 10073371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of antipsychotics for outpatients with chronic schizophrenia.
    Obradovic M; Mrhar A; Kos M
    Int J Clin Pract; 2007 Dec; 61(12):1979-88. PubMed ID: 17997804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pharmacoeconomic review of the use of injectable long-acting risperidone].
    Bartkó G; Fehér L
    Neuropsychopharmacol Hung; 2005 Dec; 7(4):199-207. PubMed ID: 16496485
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 11.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.